COMPASS Pathways Plc - American Depository Shares (CMPS)

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD. During H.C. Wainwright’s G

Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global

Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027. Speaking

COMP360 shows 39% response rate; commercial launch targeted for H1 2027.

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027. During Canaccord

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following positive Phase III results and six-month durability data from two trials. Chief Executive Officer Kabir

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory timel

Compass (CMPS) Q1 2026 Earnings Transcript

Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for a potential launch by the end of the year if the therapy is approved. On the company’s first-quar

Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression.

COMPASS Pathways PLC (NASDAQ:CMPS) shares are soaring on Monday after President Donald Trump issued an executive order directing federal health agencies to speed up the review process for psychedelic‑based treatments.

Compass Pathways may be the first to benefit from an accelerated approval process.

Trump is easing approval for psychedelic treatments for mental disorders.

Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and Reclaiming Your Life.